Market Overview
European banks are losing some of their earlier appeal among investors, despite still trading at relatively attractive valuations compared to the broader market, as concerns about slowing economic growth in Europe, weaker credit expansion, and margin pressure in a potentially lower interest rate environment continue to build. After several years of strong gains, the sector has entered a clear phase of capital rotation, with investors increasingly shifting allocations toward other areas such as technology and commodity-related equities. This week, attention is particularly focused on Thursday’s European Central Bank decision, as its guidance on the future interest rate path could significantly influence expectations for bank profitability. At the same time, the outlook for the sector remains heavily dependent on macroeconomic conditions in Europe, since any further rate hikes could support earnings, while weaker growth and rising credit risk could quickly offset that benefit.
European Session
Tuesday’s trading session in Europe is characterized by a cautiously positive tone, with major indices recovering earlier losses and posting modest gains amid improving sentiment, despite ongoing geopolitical uncertainty surrounding US–Iran negotiations and rising oil prices. The UK’s FTSE 100 is up around 0.5%, France’s CAC 40 gains 0.2%, Germany’s DAX rises 0.2%, while Spain’s IBEX outperforms with a gain of about 1%. However, markets remain sensitive to any lack of progress in peace talks and the risk of further increases in energy prices.
US–Iran
Brent crude oil remains above the $100 per barrel mark, supported by escalating tensions in the US–Iran conflict. Tehran has proposed a deal involving the reopening of a key shipping route in exchange for lifting the US blockade of Iranian ports and vessels, but without any concessions on its nuclear program, which remains unacceptable to the Trump administration.
At the same time, the US President has withdrawn plans to send a delegation to Pakistan for another round of talks, further weakening prospects for a diplomatic breakthrough and reinforcing Washington’s hardline stance. As a result, with negotiations stalled and the risk of further regional instability persisting, the oil market remains highly sensitive, keeping Brent prices elevated.
Companies
BP (BP.UK) significantly beat market expectations in the first quarter, posting a strong jump in profits driven by higher oil prices and elevated volatility linked to the US–Iran conflict. Adjusted net income rose to $3.2 billion versus $1.38 billion a year earlier and came in above analyst forecasts, while adjusted EBIT increased by around 40% year on year to $6.27 billion.
Key financial figures:
-
Adjusted net income: $3.2 billion vs $1.38 billion a year earlier, above expectations
-
Adjusted EBIT: $6.27 billion, up ~40% year on year, above consensus
-
Customers & products segment: $3.2 billion vs $677 million a year earlier, main driver of growth
-
Upstream segment: $1.98 billion, down 32% year on year
-
Earnings per share: 20.67 cents vs 8.75 cents a year earlier, above expectations
-
Dividend: 8.32 cents per share, unchanged quarter on quarter
The main driver of performance was the trading and refining segment, which benefited from extreme price volatility and supply disruptions in energy markets. However, the company continues to face pressure from weaker cash flows and rising debt levels, partially offsetting the strong earnings picture.
New CEO Meg O’Neill emphasized that the results strengthen her position to push ahead with restructuring efforts, including cost reductions and asset disposals. BP also reiterated its commitment to financial discipline and debt reduction, while warning that future results remain highly dependent on geopolitical developments and oil price dynamics.
Source: xStation5
Bayer (BAYN.US) came under pressure after a mixed hearing at the US Supreme Court regarding its attempt to limit tens of thousands of lawsuits over its Roundup herbicide. The case centers on whether federal pesticide labeling laws preempt state-level lawsuits alleging failure to warn about cancer risks.
During the hearing, some justices appeared sympathetic to Bayer’s arguments in favor of uniform federal standards, while others emphasized that individual states may still have the right to assess risk and issue warnings. The lack of a clear direction from the court weighed on sentiment and triggered a decline in the stock.
The case is critical for Bayer, which has already set aside more than $11 billion for settlements and continues to face tens of thousands of claims. A favorable ruling could significantly reduce legal risks and help resolve a long-standing issue that has weighed on the company’s valuation.
Source: xStation5
Precious Metals
Gold and silver remain under downward pressure. Geopolitical tensions linked to the US–Iran situation are failing to provide support, with gold down around 1.5% and falling below $4,650 per ounce. Silver is under stronger pressure, dropping nearly 3% and slipping below $73 per ounce.
Cryptocurrencies
Downward pressure is also visible in the cryptocurrency market, where major assets are losing ground. Bitcoin and Ethereum are both down around 1.6%, reflecting a broader deterioration in global market sentiment.
Alphabet Q1 Preview: High Bar and Pressure on Quality
📉Gold drops 1.5% as rising oil pressures precious metals
Novartis disappoints with its earnings, sending its stock down to a key support level 💥
Chart of the day 🚩USDJPY with mixed reaction to cautious Bank of Japan decision. Is stagflation heading to Japan? (28.04.2026)
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.